- Self–care describes the role of individuals in preventing disease, promoting and maintaining their mental and physical health, and actively participating in their healthcare
- A wealth of evidence [...] Read more »
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader Read more »
Fortrea lance un studio d’innovation en IA pour galvaniser les solutions technologiques et humaines afin d’améliorer la réalisation des essais cliniques
DURHAM, État de Caroline du Nord, 28 juin 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a [...] Read more »
Fortrea startet KI-Innovationsstudio, um Technologie und menschliche Lösungen zur Verbesserung der Durchführung klinischer Studien zu bündeln
DURHAM, N.C., June 28, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (CRO), gab heute die Einführung seines Innovationsstudios für künstliche Intelligenz (KI) [...] Read more »
Fortrea Lança AI Innovation Studio para Galvanizar Tecnologia e Soluções Humanas para Aprimoramento da Entrega de Ensaios Clínicos
DURHAM, N.C., June 28, 2024 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje o lançamento do seu AI Innovation Studio, [...] Read more »
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a [...] Read more »
OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications
London, June 24, 2024 (GLOBE NEWSWIRE) — June 24, 2024, London, UK – Read more »
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
Saint–Louis, France and Weil am Rhein, Germany and Zurich, Switzerland, June 24, 2024 (GLOBE NEWSWIRE) — Allecra Therapeutics (“Allecra”) and Acino today announced the signing of an exclusive licensing agreement [...] Read more »
Adalvo erhält erste Generika-Zulassung in der EU für Liraglutid-Fertigpen
SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) — Adalvo gibt die erfolgreiche DCP–Zulassung für Liraglutid–Fertigpens und damit die erste Generika–Zulassung in der EU bekannt.
Als [...] Read more »
Adalvo obtient la première approbation générique de l’UE pour son stylo prérempli de liraglutide
SAN ĠWANN, Malte, 17 juin 2024 (GLOBE NEWSWIRE) — Adalvo annonce l’approbation par procédure décentralisée de son stylo prérempli de liraglutide, soit la toute première approbation [...] Read more »
Adalvo obtém primeira aprovação genérica da UE para caneta pré-cheia com liraglutida
SAN ĠWANN, Malta, June 17, 2024 (GLOBE NEWSWIRE) — Adalvo anuncia a aprovação bem–sucedida do DCP para a caneta pré–cheia com liraglutida, marcando–a como a primeira aprovação [...] Read more »
From Awareness to Action on Global Fatty Liver Day
Global Liver Institute Unites the Field in Times of Name Changes and New Treatments
WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) — Today marks the seventh annual Read more »
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre–filled pen, marking it as the first generic approval in the EU.
As a bioequivalent version of [...] Read more »
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) — Read more »
Mediktor Acquires Sensely and Consolidates Its Position as a Leader in AI Healthcare Solutions
BARCELONA, Spain and SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) — Read more »